G J Morgan

Proteomics and the haematologist.

G. Morgan, K S Rees-Unwin, G J Morgan, 2004, Clinical and laboratory haematology.

MMSET is the key molecular target in t(4;14) myeloma

D C Johnson, G. Morgan, P. Wu, 2013, Blood Cancer Journal.

High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.

E Roman, J A Child, G. Morgan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

Caleb K. Stein, O. Stephens, B. Barlogie, 2017, Nature Communications.

Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve

R. Johnson, G. Pratt, G J Morgan, 2001, British journal of haematology.

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936

M Hummel, H E White, G. Morgan, 2003, Leukemia.